Computational Approaches for Translational Oncology: Concepts and Patents.

BACKGROUND Cancer is a heterogeneous disease, which is based on an intricate network of processes at different spatiotemporal scales, from the genome to the tissue level. Hence the necessity for the biomedical and pharmaceutical research to work in a multiscale fashion. In this respect, a significant help derives from the collaboration with theoretical sciences. Mathematical models can in fact provide insights into tumor-related processes and support clinical oncologists in the design of treatment regime, dosage, schedule and toxicity. OBJECTIVE AND METHOD The main objective of this article is to review the recent computational-based patents which tackle some relevant aspects of tumor treatment. We first analyze a series of patents concerning the purposing the purposing or repurposing of anti-tumor compounds. These approaches rely on pharmacokinetics and pharmacodynamics modules, that incorporate data obtained in the different phases of clinical trials. Similar methods are also at the basis of other patents included in this paper, which deal with treatment optimization, in terms of maximizing therapy efficacy while minimizing side effects on the host. A group of patents predicting drug response and tumor evolution by the use of kinetics graphs are commented as well. We finally focus on patents that implement informatics tools to map and screen biological, medical, and pharmaceutical knowledge. RESULTS AND CONCLUSIONS Despite promising aspects (and an increasing amount of the relative literature), we found few computational-based patents: there is still a significant effort to do for allowing modelling approaches to become an integral component of the pharmaceutical research.

[1]  D. K. Arrell,et al.  Network Systems Biology for Drug Discovery , 2010, Clinical pharmacology and therapeutics.

[2]  R. Larsson,et al.  Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs , 1995, Anti-cancer drugs.

[3]  R Simon,et al.  Bayesian Design and Analysis of Active Control Clinical Trials , 1999, Biometrics.

[4]  Vered Rom-Kedar,et al.  Novel Strategies for Granulocyte Colony-Stimulating Factor Treatment of Severe Prolonged Neutropenia Suggested by Mathematical Modeling , 2008, Clinical Cancer Research.

[5]  I. Bleiweiss,et al.  Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer , 2002, Anti-cancer drugs.

[6]  Ivar Østby,et al.  A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation , 2003, Journal of mathematical biology.

[7]  L. D. Pillis,et al.  A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth , 2005 .

[8]  P. Carmeliet,et al.  SnapShot: Tumor Angiogenesis , 2012, Cell.

[9]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[10]  Dominique Barbolosi,et al.  Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model , 2000, Comput. Biomed. Res..

[11]  Quaid Morris,et al.  Fast integration of heterogeneous data sources for predicting gene function with limited annotation , 2010, Bioinform..

[12]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[13]  P Hogeweg,et al.  Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.

[14]  Magda El-Shenawee,et al.  Computational Model of Ductal Carcinoma In Situ: The Effects of Contact Inhibition on Pattern Formation , 2009, IEEE Transactions on Biomedical Engineering.

[15]  Vittorio Cristini,et al.  Predictions of tumour morphological stability and evaluation against experimental observations , 2011, Journal of The Royal Society Interface.

[16]  D. Lauffenburger,et al.  Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.

[17]  Z Agur,et al.  Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. , 1991, Experimental hematology.

[18]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[19]  V. Brusic,et al.  Mathematical modeling for novel cancer drug discovery and development , 2014, Expert opinion on drug discovery.

[20]  Hryniuk Wm Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.

[21]  Pornpimol Charoentong,et al.  Mathematical models for translational and clinical oncology , 2013, Journal of Clinical Bioinformatics.

[22]  Fabrício F. Costa Big data in biomedicine. , 2014, Drug discovery today.

[23]  Markus Scholz,et al.  A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. , 2004, Blood.

[24]  David S Wishart,et al.  Computational systems biology in drug discovery and development: methods and applications. , 2007, Drug discovery today.

[25]  Philip Hahnfeldt,et al.  Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. , 2012, Cancer research.

[26]  L. Preziosi,et al.  A Hybrid Model Describing Different Morphologies of Tumor Invasion Fronts , 2012 .

[27]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[28]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Peter L. Bonate,et al.  Pharmacokinetic-Pharmacodynamic Modeling And Simulation , 2005 .

[30]  B. Chabner,et al.  Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.

[31]  A. Anderson,et al.  A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion , 2005 .

[32]  Zhihui Wang,et al.  Mathematical modeling in cancer drug discovery. , 2014, Drug discovery today.

[34]  Massimo Bernaschi,et al.  Computational modeling of the immune response to tumor antigens , 2005 .

[35]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[36]  L. Preziosi,et al.  A multiscale hybrid approach for vasculogenesis and related potential blocking therapies. , 2011, Progress in Biophysics and Molecular Biology.

[37]  Dong Seok Kim Cancer vaccines in the immunotherapy era: Rational approach , 2013, Human vaccines & immunotherapeutics.

[38]  R. Jain,et al.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[39]  Winston A Hide,et al.  Big data: The future of biocuration , 2008, Nature.

[40]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[41]  M. Christian,et al.  Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Karin M. Verspoor,et al.  Combining heterogeneous data sources for accurate functional annotation of proteins , 2013, BMC Bioinformatics.

[43]  H E Wichmann,et al.  Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. , 1993, Experimental hematology.

[44]  Zvia Agur,et al.  Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. , 2008, Cancer research.

[45]  A. Rossi,et al.  Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literature. , 2000, Anticancer research.

[46]  Alissa M. Weaver,et al.  Mathematical modeling of cancer: the future of prognosis and treatment. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[47]  L Preziosi,et al.  A review of mathematical models for the formation of vascular networks. , 2013, Journal of theoretical biology.

[48]  Z. Agur,et al.  The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. , 2005, Journal of theoretical biology.

[49]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[50]  Frank Pokrop Development of FDA-Regulated Medical Products , 2005 .

[51]  S Madani,et al.  Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice , 2010, Clinical pharmacology and therapeutics.

[52]  R Norel,et al.  A model for the adjustment of the mitotic clock by cyclin and MPF levels. , 1991, Science.

[53]  Vessela Kristensen,et al.  Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy , 2007, BMC Cancer.

[54]  D L S McElwain,et al.  A history of the study of solid tumour growth: The contribution of mathematical modelling , 2004, Bulletin of mathematical biology.

[55]  NOVEL DISEASE TREATMENT BY PREDICTING DRUG ASSOCATION , 2017 .

[56]  Krishnendu Chatterjee,et al.  Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.